These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 3081544

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Review of the new second-generation cephalosporins: cefonicid, ceforanide, and cefuroxime.
    Tartaglione TA, Polk RE.
    Drug Intell Clin Pharm; 1985 Mar; 19(3):188-98. PubMed ID: 3884304
    [Abstract] [Full Text] [Related]

  • 4. Use of long half-life parenteral cephalosporins in ambulatory practice.
    Sauerwein M, Deamer RL, Prichard JG.
    J Fam Pract; 1987 Jan; 24(1):47-51. PubMed ID: 3794613
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Summary of comparative clinical studies of ceftizoxime and cefamandole, cefazolin and tobramycin.
    Duma RJ.
    J Antimicrob Chemother; 1982 Nov; 10 Suppl C():303-9. PubMed ID: 6296025
    [No Abstract] [Full Text] [Related]

  • 7. Cefamandole nafate therapy of respiratory tract, skin, and soft tissue infections in 74 patients.
    Perkins RL, Fass RJ, Warner JF, Prior RB, File TM, Tight RR, Gardner WG, Ruiz DE, Slama TG.
    J Infect Dis; 1978 May; 137 Suppl():S110-S118. PubMed ID: 418126
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Use of antibiotics. Cephalosporins.
    Wise R.
    Br Med J; 1978 Jul 01; 2(6129):40-2. PubMed ID: 678801
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Review of cefonicid, a long-acting cephalosporin.
    Dudley MN, Quintiliani R, Nightingale CH.
    Clin Pharm; 1984 Jul 01; 3(1):23-32. PubMed ID: 6365414
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The role of the extended half-life second-generation cephalosporins in surgical prophylaxis.
    Rapp RP, Blue D.
    Drug Intell Clin Pharm; 1985 Mar 01; 19(3):214-6. PubMed ID: 3979267
    [No Abstract] [Full Text] [Related]

  • 15. Comparative in vivo efficiency of cefamandole and cefoxitin against Bacteroides fragilis.
    Bergeron MG, Gauvreau L, Nguyen BM.
    Scand J Infect Dis Suppl; 1980 Mar 01; suppl 25():60-5. PubMed ID: 6937954
    [Abstract] [Full Text] [Related]

  • 16. Cefonicid: a long-acting, second-generation cephalosporin. Antimicrobial activity, pharmacokinetics, clinical efficacy and adverse effects.
    Pontzer RE, Kaye D.
    Pharmacotherapy; 1984 Mar 01; 4(6):325-33. PubMed ID: 6393074
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Comparative trial of cefonicid and cefamandole in the therapy of community-acquired pneumonia.
    Wallace RJ, Niefield SL, Waters S, Waters B, Awe RJ, Wiss K, Martin RR, Greenberg SB.
    Antimicrob Agents Chemother; 1982 Feb 01; 21(2):231-5. PubMed ID: 7041813
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Cefonicid: an overview of clinical studies in the United States.
    Jacob LS, Layne P.
    Rev Infect Dis; 1984 Feb 01; 6 Suppl 4():S791-802. PubMed ID: 6395272
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.